Clinical trials: Indolent Lymphoma
Diffuse Large B-cell Lymphoma, de Novo DLBCL
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
- Conditions
- Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
- Trial name
- PIX-R (NCT01321541)
- Testing
- Pixantrone + Rituximab, Gemcitabine + Rituximab
- Where
- 131 sites in United States, Austria and 15 more
- Volunteers
- 312 people
- Sponsor
- CTI BioPharma
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Indolent B-cell Non-Hodgkin's Lymphoma
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing schedule.
- Trial name
- NCT01933516
- Testing
- GP2013
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Sandoz
Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
This is an observational study, in which data from Taiwanese people with indolent non-Hodgkin lymphoma who will be receiving copanlisib is studied.
- Trial name
- NCT05217914
- Testing
- Copanlisib (BAY80-6946)
- Where
- Taiwan
- Volunteers
- 6 people
- Sponsor
- Bayer
Lymphoma, Follicular, Lymphoma, Small Lymphocytic
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Primary Objectives: To document the efficacy of treatment with autologous lymphoma-derived HSPPC-96 of selected patients with indolent lymphoma.
- Trial name
- NCT00081809
- Testing
- autologous human tumor-derived HSPPC-96
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Agenus Inc.
Follicular Lymphoma (FL), Non Hodgkin Lymphoma
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL…
- Conditions
- Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04745832
- Testing
- Zandelisib, Rituximab, Bendamustine
- Where
- 141 sites in United States, Australia and 17 more
- Volunteers
- 82 people
- Sponsor
- MEI Pharma, Inc.
Non-Hodgkin's Lymphoma
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera.
- Trial name
- NCT01153971
- Testing
- rituximab
- Where
- 15 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Marginal Zone Lymphoma, Follicular Lymphoma
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
This was a multicenter, open-label, phase 2 study to evaluate efficacy, safety, and tolerability of BGB-3111 (zanubrutinib) 160 milligrams (mg) twice daily (BID) in combination with rituximab in Chinese participants with…
- Conditions
- Marginal Zone Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03520920
- Testing
- Zanubrutinib, Rituximab
- Where
- 4 sites in China
- Volunteers
- 41 people
- Sponsor
- BeiGene
Non-Hodgkin's Lymphoma
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
This is an open-label, multicenter, Phase I/II study of the safety of escalating doses of single-agent PRO131921 in patients with relapsed or refractory CD20-positive indolent NHL.
- Trial name
- NCT00452127
- Testing
- PRO131921
- Volunteers
- 26 people
- Sponsor
- Genentech, Inc.
Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Low-Grade
- Trial name
- NCT00060671
- Testing
- rituximab, Pixantrone (BBR 2778)
- Where
- 38 sites in United States
- Volunteers
- 800 people
- Sponsor
- CTI BioPharma
Lymphoma
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00258336
- Testing
- autologous immunoglobulin idiotype-KLH conjugate vaccine, rituximab, sargramostim
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Favrille
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- NCT02640833
- Testing
- Duvelisib, Venetoclax
- Where
- 10 sites in United States
- Sponsor
- AbbVie
Indolent B-cell Non-Hodgkin's Lymphoma
Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ME-401 in the treatment of Japanese participants with Relapsed or Refractory indolent B-Cell Non-Hodgkin's Lymphoma.
- Trial name
- NCT04533581
- Testing
- ME-401
- Where
- 30 sites in Japan
- Volunteers
- 61 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the potential drug-drug interactions between ofatumumab and bendamustine in subjects with previously untreated or relapsed indolent B-cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT01691807
- Testing
- ofatumumab, bendamustine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
A Single-arm, Phase Ⅰ/Ⅱ Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of ATG-010 in Combination with Lenalidomide and Rituximab (R2) in Adult Patients with Relapsed/Refractory DLBCL and iNHL Who are…
- Trial name
- SWATCH (NCT05265975)
- Testing
- ATG-010, Lenalidomide, Rituximab
- Where
- 6 sites in China
- Volunteers
- 54 people
- Sponsor
- Antengene Corporation
Non-Hodgkin Lymphoma by Clinical Course
Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma
The purpose of this study is to determine whether bendamustine HCl for injection is safe and effective in the treatment of Rituximab refractory or relapsed B-cell indolent lymphoma.
- Trial name
- NCT01570049
- Testing
- Bendamustine
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
Indolent B-Cell Non-Hodgkin Lymphoma
A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory…
- Trial name
- NCT03571568
- Testing
- BI-1206, Rituximab, Acalabrutinib
- Where
- 27 sites in United States, Brazil and 4 more
- Volunteers
- 140 people
- Sponsor
- BioInvent International AB
Non-Hodgkin's Lymphoma
A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)
This open-label, randomized study will assess the efficacy and safety of obinutuzumab (RO5072759) in combination with chemotherapy compared to rituximab (MabThera/Rituxan) with chemotherapy followed by obinutuzumab or rituximab…
- Trial name
- NCT01332968
- Testing
- Obinutuzumab, Cyclophosphamide, Doxorubicin
- Where
- 183 sites in United States, Australia and 16 more
- Volunteers
- 1,401 people
- Sponsor
- Hoffmann-La Roche
Indolent B-cell NHL
A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.
To compare the efficacy of bendamustine against treatment of physician's choice on progression-free survival in subjects with indolent B-cell NHL.
- Trial name
- ROBIN (NCT01289223)
- Testing
- Bendamustine IV, Treatment of Physicians Choice
- Where
- 3 sites in Australia, Slovakia
- Volunteers
- 88 people
- Sponsor
- Mundipharma Research Limited
Non-Hodgkin's Lymphoma
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients
This is a Phase II single arm study of a novel T cell immunotherapy in patients with indolent non-Hodgkin's lymphoma (NHL). Eligible patients will have relapsed or refractory disease after receiving at least one and no more than…
- Trial name
- NCT00081783
- Testing
- Xcellerated T Cells
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Xcyte Therapies